, Cancer, prostate-National Comprehensive Cancer Network guidelines for treatment of Cancer by site, 2018.
Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, vol.67, pp.1028-1038, 2015. ,
Acquisition with 11 C-choline and 18 F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and metaanalysis, Ann Nucl Med, vol.30, pp.385-392, 2016. ,
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, vol.71, pp.618-629, 2017. ,
Comparison of choline-PET/ CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skelet Radiol, vol.43, pp.1503-1513, 2014. ,
Impact of 18 F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry, J Nucl Med, vol.55, pp.574-581, 2014. ,
Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18 F-NaF PET/CT and whole body 1.5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial, Acta Oncol, vol.55, pp.59-67, 2016. ,
A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor, Ann Nucl Med, vol.24, pp.523-531, 2010. ,
Whole-body diffusion-weighted MRI compared with 18 F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma, Am J Roentgenol, vol.199, pp.1114-1120, 2012. ,
Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment, Eur Rev Med Pharmacol Sci, vol.20, pp.3770-3776, 2016. ,
Detection of bone metastases in patients with prostate cancer by 18 F fluorocholine and 18 F fluoride PET-CT: a comparative study, Eur J Nucl Med Mol Imaging, vol.35, pp.1766-1774, 2008. ,
Fluorocholine ( 18 F) and sodium fluoride ( 18 F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading, Q J Nucl Med Mol Imaging, vol.55, pp.448-457, 2011. ,
, Guideline on clinical evaluation of diagnostic agents, In: Guidel. Clin. Eval. Diagn. Agents, 2009.
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy, J Urol, vol.172, pp.42-46, 2004. ,
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy, Eur Urol, vol.67, pp.1009-1016, 2015. ,
Prostate cancerspecific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, vol.299, pp.2760-2769, 2008. ,
EAU-ESTROSIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, vol.71, pp.630-642, 2017. ,
Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey, Radiol Oncol, vol.48, pp.20-28, 2014. ,
Combined 18F-fluorocholine and 18 F-fluoride positron emission tomography/ computed tomography imaging for staging of high-risk prostate cancer, BJU Int, vol.110, pp.1501-1506, 2012. ,
Clinical impact of 18 F-choline PET/CT in patients with recurrent prostate cancer, Eur J Nucl Med Mol Imaging, vol.39, pp.936-943, 2012. ,
18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: detection rate, impact on management and adequacy of impact. A prospective multicentre study, PLoS One, vol.13, p.191487, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01802330
Impact of 11 C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial, Eur J Nucl Med Mol Imaging, vol.41, pp.2222-2231, 2014. ,
Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), Eur Radiol, vol.20, pp.2973-2982, 2010. ,
The future of choline pet in the era of PMSA, Q J Nucl Med Mol Imaging, vol.18, pp.3062-3067, 2018. ,
Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18, 2014. ,
based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.11-20 ,
Prospective comparison of 18 F-fluoromethylcholine versus 68 Ga-PSMA PET/ CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med, vol.56, pp.1185-1190, 2015. ,
, TEP/TDM et récidive biologique d'adénocarcinome prostatique: apport du, p.68, 2017.
, Ga-PSMA-11 lorsque la 18 F-fluorocholine n'est pas contributive, Prog En Urol, vol.27, pp.474-481
, , 2017.
, Ga-PSMA-11 quand la 18 F-fluorocholine ne localise pas la récidive biologique du cancer de la prostate : à propos d'un cas et revue de la littérature